Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SILICOFCM: Sacubitril/Valsartan vs Lifestyle in HCM
NCT03832660Phase 2Completed
- Sponsor
- Newcastle University
- Start
- May 2019
- Primary completion
- May 2022
- Modality
- Small Molecules
- Countries
- 4
01
Overview
Phase 2, randomised, open-label trial of sacubitril + valsartan in hypertrophic cardiomyopathy (HCM), sponsored by Newcastle University. Primary endpoint: Peak Oxygen Consumption at 4 months. Started May 2019; status: completed.
02
Drugs
sacubitril + valsartan
03
Conditions
hypertrophic cardiomyopathy (HCM)
Beyond the preview
Go deeper on NCT03832660.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03832660.